This disclosure provides compounds of Formula (I) (e.g., Formula (I-1), Formula (I2), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), or (I-a-4)), Formula (I-b) (e.g., Formula (I-b-1), (I-b-2), (I-b-3), or (I-b-4)), Formula (I-c) (e.g., Formula (I-c-1) or (I-c-2)), Formula (I-d) (e.g., Formula (I-d-1)), or Formula (I-e) (e.g., Formula (I-e-1) or (I-e-2))), Formula (II), or Formula (II-a) (e.g., Formula (II-a-1)), or pharmaceutically acceptable salts thereof, that induce degradation of a BCL6
protein. These compounds are useful, for example, for treating a
cancer in a subject (e.g., a human). This disclosure also provides compositions containing the compounds provided herein, or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.